Induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) hold promise for assessment of drug-induced arrhythmias and are being considered for use under the comprehensive in vitro proarrhythmia assay (CiPA). We studied the effects of 26 drugs and 3 drug combinations on 2 commercially available iPSC-CM types using high-throughput voltage-sensitive dye and microelectrode-array assays being studied for the CiPA initiative and compared the results with clinical QT prolongation and torsade de pointes (TdP) risk. Concentration-dependent analysis comparing iPSCCMs to clinical trial results demonstrated good correlation between drug-induced rate-corrected action potential duration and field potential duration (APDc and FPDc) prolongation and clinical trial QTc prolongation. Of 20 drugs studied that exhibit clinical QTc prolongation, 17 caused APDc prolongation (16 in Cor.4U and 13 in iCell cardiomyocytes) and 16 caused FPDc prolongation (16 in Cor.4U and 10 in iCell cardiomyocytes). Of 14 drugs that cause TdP, arrhythmias occurred with 10 drugs. Lack of arrhythmic beating in iPSC-CMs for the four remaining drugs could be due to differences in relative levels of expression of individual ion channels. iPSC-CMs responded consistently to human ether-a-go-go potassium channel blocking drugs (APD prolongation and arrhythmias) and calcium channel blocking drugs (APD shortening and prevention of arrhythmias), with a more variable response to late sodium current blocking drugs. Current results confirm the potential of iPSC-CMs for proarrhythmia prediction under CiPA, where iPSCPublished by Oxford University Press on behalf of the Society of Toxicology 2016. This work is written by US Government employees and is in the public domain in the US.
Between 1988 and 2009, 14 drugs were removed from the market worldwide as a result of their potential to induce lifethreatening cardiac arrhythmias (Stockbridge et al., 2013) . Regulatory agencies responded by requiring new drugs to be assessed for their ability to block the human ether-a-go-go (hERG) potassium channel and prolong the QT interval on the electrocardiogram (2005a,b) . While testing for hERG potassium channel inhibition and QT prolongation has prevented torsade de pointes (TdP) inducing drugs from reaching the market, other new drugs are dropped from development, sometimes inappropriately (Stockbridge et al., 2013) . This may especially be true for the drugs that have multichannel effects, where the deleterious effect of hERG potassium channel block may be balanced out by the drug effect on inward currents, as is the case for several marketed drugs (e.g., verapamil also blocks L-type calcium current, ranolazine blocks late sodium current) (Johannesen et al., 2014) . This has been the driving factor for the development of a new comprehensive in vitro proarrhythmia assay (CiPA) Fermini et al., 2016; Sager et al., 2014) .
The CiPA calls for a three-pronged preclinical approach. First, is to assess the effect of a drug on multiple isolated cardiac ion channels (e.g. hERG, L-type calcium, sodium) in patch clamp assays. Second, is to reconstruct the human ventricular action potential with in silico simulations to predict the proarrhythmic liability of the drug. Third, is to perform integrated cellular studies with human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Complementary phase 1 electrocardiographic (ECG) data will then be collected with ECG biomarkers that can differentiate the effects of multichannel block (Sager et al., 2014) .
The goal of this study was to perform a thorough characterization of the current state of iPSC-CMs technologies to predict drug proarrhythmic risk by assessing a large number of drugs in a blinded pre-planned study to advance regulatory science in this field. Discovery of reprogramming of somatic cells into pluripotent stem cells (Takahashi et al., 2007; Takahashi and Yamanaka, 2006) , and the consequent development of the processes required to differentiate human iPSCs into functional human cardiomyocytes (Burridge et al., 2012; Kattman et al., 2011; Laflamme et al., 2007; Yang et al., 2008) created the basis for the growing use of iPSC-CMs for cardiotoxicity screening of drugs (Clements and Thomas, 2014; Gibson et al., 2014; Guo et al., 2011; Harris et al., 2013; Ma et al., 2011; Navarrete et al., 2013) . Here we perform a comprehensive assessment of the proarrhythmic potential of 26 drugs in two commercially available iPSC-CM cell lines. The electrophysiology response of the iPSC-CMs is assessed with microelectrode arrays (MEA) and optical imaging of voltage-sensitive dyes (VSD), technologies under consideration for inclusion in the CiPA screening paradigm due to promising preliminary correlation for clinically arrhythmogenic compounds (Clements and Thomas, 2014; Harris et al., 2013) . With these technologies, we focus on their ability to measure prolonged repolarization -action potential duration (APD) with VSD and field potential duration (FPD) by MEA -and detect the presence of arrhythmic events in vitro.
Unique to this study, we compare the iPSC-CM results with the individual ion channel effects for the multiple ion channels being studied under CiPA and characterized expression of the corresponding encoding genes in two iPSC-CMs lines: Rapidly activating delayed rectifier potassium current (IKr), encoded by hERG gene, L-type calcium current (ICaL), encoded by Cav1.2, and late sodium current (late-INa), encoded by Nav1.5, which are the three channels primarily affected by the drugs in this study . Gene expression data were also obtained for KCNQ1 gene, encoding slow voltage-gated potassium channel (IKs current). In addition, we performed a comparison between the concentration-dependent response of iPSC-CMs to eight drugs and three drug combinations recently studied in clinical trials. Finally, we performed iPSC-CMs experiments with chronic exposure to drugs for up to 72 h.
METHODS
iPSC-CMs. Two commercially available iPSC-CMs cell lines were used in this study: iCell (Cellular Dynamics International) and Cor.4U (Axiogenesis AG). According to the manufacturers, iCell and Cor.4U were 100% and 95% pure iPSC-cardiomyocytes correspondingly, representing a mix of ventricular-, atrial-, and nodal-like cells (see Supplementary Methods for specific lot information).
RNA extraction and real-time qRT-PCR. Total RNAs of human adult left ventricle were purchased from Clontech (Mountain View, California). Total RNAs from iCell and Cor.4U iPSC-CMs were prepared with miRNeasy Mini Kit (Qiagen, Hilden, Germany), and reverse transcribed into cDNA using RT 2 First Strand kits (SABiosciences/Qiagen). The Clontech total RNA was pooled from three different samples. The RNAs for iCells and Cor.4U cells were isolated from cells cultured in three different wells of single experiment. SYBR green-based real-time qRT-PCR was performed on the CFX96 PCR detection system (Bio-Rad, Hercules, North Carolina ) with gene-specific primers (SABiosciences), mRNA expression were normalized to b-actin.
Manual patch clamp. Stably transfected hERG, Nav1.5 cells (HEK-293), or Cav1.2 cells (CHO) were obtained from Cytocentrics Biosciences (Rostock, Germany). Cells were maintained according to the supplier instructions. The external solution had an ionic composition of (in mM): 137 NaCl, 4 KCl, 1.8 CaCl2, 1.2 MgCl2, 11 dextrose, 10 HEPES, adjusted to a pH of 7.4 with NaOH. The internal (pipette) solution had an ionic composition of (in mM): 130 KCl; 1 MgCl2, 5 NaATP, 7 NaCl, 5 EGTA, 5 HEPES, pH ¼ 7.2 using KOH. Currents were measured at 36 6 1 C and 0.1
Hz pacing rate using the whole-cell variant of the patch-clamp method (Crumb et al., 1995) . After rupture of the cell membrane, current amplitude, and kinetics were allowed to stabilize (3-5 min) before recordings. Currents were elicited using a ventricular action potential waveform (for hERG and Cav1.2) or a voltage waveform with a holding potential of À90 mV and pulsing to À15 mV for 40 ms (Nav1.5). Late Nav1.5 was elicited with the addition of 50 lM veratridine to the external solution and was measured at the end of the 40 ms pulse. Relative block of current amplitude was measured as peak current amplitude after a steady-state effect had been reached in the presence of drug relative to current amplitude before drug addition.
MEA and VSD recordings of drug-induced effects in iPSC-CMs. One hundred percent -confluent and synchronously beating Cor.4U and iCell cardiomyocyte monolayers were maintained according to manufacturer's instructions (Supplementary Methods) and assayed using an MEA system (Maestro, Axion BioSystems, Atlanta, Georgia) and a VSD system (CellOPTIQ, Clyde Biosciences, UK) at 37 C and 5% CO 2 . MEA and VSD recordings were performed 10-14 days post-thaw in iCell cardiomyocytes and 5-10 days post-thaw in Cor.4U cardiomyocytes. Drug effects were studied in serum-free conditions at four doses (Supplementary Table 1 ) by increasing drug concentration in the same well (n ! 3 wells) in acute experiments (up to 5 h drug exposure time, Supplementary Fig. 1 ) or by applying a single dose in each well in chronic experiments (up to 72 h). Positive (dofetilide, lidocaine, and diltiazem) and negative (untreated and vehicle, 0.1% dimethyl sulfoxide) controls were repeated on each plate. Extracellular FPD and cellular membrane APD data were recorded and analyzed off-line using AxIS (Axion Biosystems) and CellOPTIQ (Clyde Biosciences) software, respectively. The Fridericia formula (Fridericia, 2003) was used to correct APD and FPD dependence on beating rate ( Supplementary  Fig. 2 ) (Johannesen et al., 2014) . Vehicle-and baseline-corrected APD at 90% repolarization (DDAPD90c) and FPD (DDFPDc) were calculated for the drugs at each dose and used to compare with the similarly calculated clinical DDQTc (Johannesen et al., 2014 . Drug-induced arrhythmias were monitored with both platforms (Fig. 1) . VSD-recorded arrhythmias were classified into four categories: Type A (single notch), Type B (multiple notches), Type C (ectopic beat), and Type T (tachyarrhythmic).
In the MEA dataset, corresponding arrhythmic events (Asakura et al., 2015) were collectively identified as "arrhythmic beats", as shown in Figure 1 . In both MEA and VSD recordings, it was observed that some of the tested drugs inhibited spontaneous beating in the cells leading to a "quiescent" state (Q). The operators of MEA and VSD systems were blinded to treatment at the time of the recordings and data analysis.
Statistical analysis. MEA and VSD data were analyzed using a linear-mixed effects model, where the data from untreated and vehicle control were combined and used as control. The differences for each dose were reported as the least-squares mean (95% confidence interval) of the difference between that dose and the corresponding time-matched control, using PROC MIXED in SAS 9.2 (SAS Institute, Cary, NC). A linear mixed-effects model was used to quantify the relationship between QTc and plasma drug concentration with concentration as a fixed effect and subject as a random effect on intercept and concentration.
RESULTS
Baseline Electrophysiological Characteristics of iPSC-Cardiomyocytes iPSC-CMs selected for this study exhibited spontaneous membrane depolarization. Baseline electrophysiological characteristics of spontaneous beating in Cor.4U and iCell cardiomyocytes are summarized in the Supplementary 
Ion Channel Gene Expression
The main ion channel currents (with corresponding gene and channel names) affected by the drugs selected for the current study were IKr (KCNH2; hERG), ICaL (CACNA1C; Cav1.2), INa (SCN5A; Nav1.5), and IKs (KCNQ1/minK; KvLQT1). Nav1.5 channel is responsible for both, peak sodium current (peak-INa, not TTXsensitive) and the late sodium current (late-INa, TTX-sensitive).
As we recently reported, the effect of the selected drugs on the other ion channels was minimal (Crumb, Jr. et al., 2016) . We compared the expression of the genes encoding these four channels with the expression levels in adult primary human ventricular cardiomyocytes (Fig. 2) . For outward IKr current, iCells had less and Cor4.U had more hERG expression than adult cardiomyocytes, whereas both iPSC-CM cell types had less KCNQ1 expression (outward IKs current). For inward currents (ICaL and INa), both iCells and Cor4.U had more Cav1.2 gene expression and less Nav1.5 gene expression than adult cardiomyocytes. The differences in hERG and Cav1.2 expression between iCells and Cor4.U are consistent with iCells having a longer APD than Cor4.U at baseline, as less outward current (IKr) and more inward current (ICaL) should both contribute to a longer APD.
Effects of Dofetilide, Quinidine, Moxifloxacin, Ranolazine, and Verapamil on iPSC-Cardiomyocytes, and Comparison to Clinical QTc For these five drugs, we compared in vitro data with the information obtained in two recent FDA-sponsored clinical trials (Johannesen et al., 2014 . Representative MEA and VSD profiles in Cor.4U and iCell cardiomyocytes before and after drug addition for the five drugs are shown in Supplementary Figure  3 . The iPSC-CM response (DDAPDc and DDFPDc, and arrhythmias) is shown in Figure 3 , along with the corresponding clinical QTc response and ion channel blockade dose-response relationships from patch clamp experiments with ion channels underlying three ventricular currents: hERG (IKr), Cav1.2 (ICaL), and Nav1.5 (late-INa). Data for all drugs studied in the acute experiments is provided in Supplementary Figure 4 (A-Y). Dofetilide, a drug associated with well-characterized clinical QTc prolongation and TdP (Pfizer, 1999) , and which blocks hERG potassium channel exclusively in the tested dose range, induced a concentration-dependent prolongation of APDc and FPDc as well as arrhythmias in both Cor.4U and iCells. The degree of APDc and FPDc prolongation in iPSC-CMs was greater than that for clinical QTc. In vitro arrhythmias occurred at doses !2 nM, the approximate C max from the clinical trial (Johannesen et al., 2014) . At the highest studied dofetilide dose (6 nM, approximately 3Â Cmax), both cell types exhibited arrhythmic beating in both VSD and MEA recordings. Of note, different patterns of arrhythmic beating occurred in the different cell types (see table inserts in Supplementary Figure 4 for the summary of observed arrhythmias). iCells first developed early afterdepolarizaions (EADs) ( Fig. 1 : Type A arrhythmia), escalating to multiple EADs (Type B) and then ectopic beats (Type C), whereas Cor.4U cardiomyocytes preferentially developed tachyarrhythmic behavior (Type T arrhythmia).
Like dofetilide, quinidine is associated with clinical QTc prolongation and TdP (Pharm. Res. Assoc., 1999). Quinidine induced a dose-dependent increase in APDc and FPDc in both iCell and Cor.4U cardiomyocytes (Fig. 3) . No arrhythmias occurred at the first dose (300 nM), but at 900 nM (approximately clinical Cmax) arrhythmias were detected in both MEA and VSD signals for 100% (6/6) of wells containing iCells, but not for those with Cor.4U cardiomyocytes. At the highest studied dose (5.4 mM, or approximately 6.4Â Cmax), all wells of the iPSC-CMs showed either arrhythmias or a cessation of spontaneous beating. The patch clamp data supports that the effect of quinidine on iPSCCMs results primarily from hERG potassium channel block in the studied concentration range.
At standard clinical concentrations moxifloxacin induces approximately 5% hERG potassium channel block and 10 ms of QTc prolongation (Florian et al., 2011) , and in our clinical study a supratherapeutic dose of intravenous FIG. 2. iPSC-CM ion channel gene expression profiles. Expression of the genes encoding four ion channels: SCN5A (Nav1.5), CACNA1C (Cav1.2), KCNH2 (hERG), and KCNQ1 in human primary adult cardiac tissue and human iPSC-CMs (normalized to adult primary levels). Data represent means 6 SD for n ¼ 3 replicates. Stars indicate statistically significant differences (P < .05).
moxifloxacin caused a QTc prolongation of 30 ms. At similar concentrations, the iPSC cardiomyocytes did not show statistically significant APDc or FPDc prolongation, but moxifloxacin caused concentration-dependent APDc and FPDc prolongation above this range (21-200 mM), and arrhythmias were detected in in both cell types at approximately 50-fold clinical Cmax.
Ranolazine causes strong block of channels underlying both the IKr (hERG) and late-INa (Nav1.5) currents ( FPDc prolongation (< 150 ms) without arrhythmias in ranolazinetreated cells.
Verapamil in particular represents a case where multichannel drug-induced effects likely underlie the clinical safety. Verapamil causes strong hERG potassium channel block, and even more potent L-type calcium channel block (Fig. 3) . Even at hERG channel block of approximately 75%, no arrhythmias were observed in iPSC-CMs. The Cor.4U cells stopped beating at !150 nM, likely due to strong ICaL block. In iPSC-CMs, verapamil caused significant concentration-dependent APDc and FPDc shortening in both cell types, whereas no QTc shortening was observed in the clinical study (Johannesen et al., 2014) . This is likely due to the greater sensitivity of iPSC-CMs to ICaL block, consistent with higher expression of Cav1.2 as compared to human adult left ventricle. The higher doses of verapamil studied in iPSC-CMs were also much greater than clinical concentrations.
Summary Results for 25 Drugs Studied in Acute Experiments
Figures 4 and 5 summarize effects of all drugs on APDc (Fig. 4) and FPDc (Fig. 5) given dose, Cor.4U cells were more likely to stop beating than iCells; however, this was often at >50Â Cmax concentrations.
The majority of arrhythmias in iPSC-CMs occurred with 60-80% hERG channel block. This is illustrated in Supplementary  Figure 5 , which shows the amount of hERG block present at the drug concentration where arrhythmias first developed. Notable drugs that exhibited strong hERG channel block (i.e. >60%) at higher concentrations but did not develop arrhythmias include ritonavir, mibefradil, bepridil, chlorpromazine, amitriptyline, terfenadine, amiodarone, azithromycin, and verapamil. With the exception of bepridil and azithromycin, all of those drugs caused Cav1.2 or Nav1.5 (late) block (> 50%). This is consistent Of the 12 drugs with TdP risk indicated on FDA labels, arrhythmias were detected in at least one iPSC-CM type for 7 drugs for both platforms, but often at a concentration greater than standard clinical Cmax. Five drugs that have TdP risk on the FDA label, but did not cause arrhythmias in iPSC-CMs even at doses significantly exceeding clinical, were amiodarone, azithromycin, bepridil, chlorpromazine, and terfenadine. The absence of arrhythmias for amiodarone, chlorpromazine, and bepridil in iPSC-CMs may be related to potent ICaL block ( Supplementary Fig. 4) , and higher-than-native expression levels of Cav1.2 in iPSC-CMs (Fig. 2) .
Cibenzoline and sertindole have not been approved in the United States; however, published clinical data exists showing clinical QTc prolongation for both, and TdP risk for sertindole (Redfern et al., 2003 Of the 11 drugs that do not have TdP risk on the FDA label, arrhythmias were detected for only two by MEA with nilotinib for both cell types and by VSD for iCells, and for ranolazine in MEA for iCells. However, this occurred only at concentrations exceeding clinical by 12-fold for ranolazine and 100-fold for nilotinib.
Overall, iPSC-CMs assay demonstrated 100% specificity (none of the clinically safe drugs induced APD/FPD prolongation in the studied dose range), 79% sensitivity for Cor.4U cardiomyocytes on both platforms, 63% for iCells on VSD, and 47% for iCell on MEA platform (see Supplementary Table 4 for details on sensitivity and specificity calculation). These results suggest that while the general response to the studied drugs in all four cell type/combinations were similar, there was variation between the two cell types.
Drug Combinations -hERG, Late Sodium and Calcium Channel Block
Coapplication of drugs that block outward ionic currents (i.e. lateINa or ICaL) to balance QTc prolongation due to hERG blockade was tested in our recent clinical study . To see whether such effects could be observed in vitro, we studied the ability of the late-INa blockers lidocaine and mexiletine and ICaL blocker diltiazem to remediate the effect of IKr block from dofetilide and moxifloxacin in iPSC-CMs. Diltiazem caused substantial reversal of moxifloxacin-induced APDc and FPDc prolongation, and eliminated arrhythmias (Fig. 7) . This effect did not occur in the clinical study; but interpretation there was confounded by the accumulation of a moxifloxacin metabolite . Both late-INa current blockers substantially shortened QTc prolongation from dofetilide in our recent clinical study . In iPSC-CMs, late-INa block did not cause consistent shortening of APDc or FPDc or elimination of arrhythmias, although this did occur with some combinations of cell type/platform (Supplementary Fig. 6 ). Lidocaine and mexiletine also had little effect on APDc or FPDc on their own ( Supplementary Fig. 3 ), which may be due to lower expression of Nav1.5 in iPSC-CM versus adult left ventricle (Fig. 2) .
Chronic Effects
The stability of the spontaneous beating phenotype in cultures of iPSC-CMs (Guo et al., 2013) allows prolonged drug exposure to be tested, a scenario that more closely parallels the repeated clinical dosing of most drugs. We thus studied the effects of six drugs on iPSC-CMs during chronic exposures: 72 h post-dose in the MEA platform (Fig. 8 ) and 24 h post-dose with the VSD platform ( Supplementary Fig. 7 ). Chronic effects of the drugs beyond 24 h were not studied with VSD platform to avoid repeated cell staining required for the longer term recordings. Results were QT "and TdP on the FDA label Quinidine
Twenty-five drugs studied in acute iPSC-CM experiments are divided into four categories based on the presence of QTc prolongation and TdP reports on the FDAapproved label. Symbol means that drug induced statistically significant (P-value <.05) and above the threshold change in APDc or FPDc for at least one of the doses.
The threshold for each cell type-assay combination was set at the two standard deviations of the variability in APDc/FPDc measurements in the control (no drug) wells.
Drug-induced FPDc or APDc prolongation (") shortening (#) or no effect (-) are shown. The cross symbol (3) means that the corresponding drug induced arrhythmias in at least 30% of the replicate wells.
a Cibenzoline (QTc "), sertindole (QTc ", TdP) (Redfern et al., 2003) .
consistent between MEA and VSD platform at 24 h for the studied drugs. Pentamidine, dofetilide, amiodarone, and nilotinib generally caused progressively increasing APDc and FPDc over the course of the exposure, and the rate of change generally increased with dose (Fig. 8 ). An exception for these compounds was that prolongation of FPDc by dofetilide showed no time dependence for Cor.4U cells. It is notable that amiodarone did not affect APDc in acute experiments, but induced APDc prolongation in both cell types after 24 h. Effects of diltiazem and lidocaine on APDc or FPDc had no time dependence in these experiments in either cell type and diltiazem-induced DDFPDc shortening decreased after longer exposure (24-72 h) in both cell types (data not shown).
DISCUSSION
This study provides a comprehensive assessment of electrophysiology and pharmacodynamic responses of two commercially available types of human iPSC-CMs in high-throughput assays, with quantitative comparisons to data for block of isolated ion channels and effects on clinical QTc. This type of mechanistic multiparameter characterization is critical for potential regulatory implementation of iPSC-CMs under a CiPA paradigm Fermini et al., 2016; Sager et al., 2014) . We observed concentration-dependent responses of both APDc and FPDc similar to clinical QTc prolongation for a series of drugs in recent FDA-sponsored clinical studies (Johannesen et al., 2014 . For some drugs (e.g. dofetilide and quinidine), the prolongation was greater in iPSC-CMs compared with clinical QTc prolongation. In addition, iPSC-CM arrhythmias developed at or near clinical concentrations (Fig. 6) , consistent with the known torsade de pointes risk of dofetilide and quinidine (Kolb et al., 2008; Nagra et al., 2005; Reiffel, 2005; Wroblewski et al., 2012 ). An advantage of our study is the approach that was taken to drug dose selection. Whereas many previous studies test drugs in a pre-specified dose range regardless of the individual drug potency or clinical use, the lowest dose for each drug in our study was generally set to the clinical Cmax and then increased in intervals informed by pre-existing literature on individual ion channel block . Because significant variability in assay conditions exists in the literature, we report comparisons to manual patch experiments at physiological conditions using the same protocols for 25 drugs tested in the iPSC-CM experiments . The ion channel data support that block of hERG, Cav1.2, and Nav1.5 (for late-INa) are most important for predicting TdP risk. In general, strong hERG block causes EADs and arrhythmias, whereas multichannel block involving Cav1.2 and Nav1.5 can prevent arrhythmias due to hERG blockade. Above a certain threshold for extreme hERG block (approximately 75% block), arrhythmias or cessation of beating often develop even with multichannel block, except for instances of extremely strong Cav1.2 block (e.g. verapamil).
While our primary focus was on the potential for drugs to acutely induce prolongation of the action potential, for a subset of drugs we also monitored APDc and FPDc during sustained chronic exposures lasting 1 (VSD) or 3 (MEA) days, which may more closely approximate clinical exposure for many drugs. For 4 drugs (pentamidine, nilotinib, dofetilide, and amiodarone) we observed progressive increases during the exposure period in APDc and FPDc beyond values obtained for acute exposure. For pentamidine, this effect is consistent with the previously described interruption of the trafficking of hERG potassium channels to the cell membrane (Kuryshev et al., 2005) . The effect of nilotinib on spontaneous beating in IPSC-CMs has been described previously, and may be related to observed cytotoxicity during prolonged exposure (Doherty et al., 2013) . For amiodarone, no effect was observed for acute exposure, and evolution of APDc and FPDc prolongation could thus be due to conversion to the active desethyl metabolite (Talajic et al., 1987) . Finally drug-induced increases in relative levels of channels carrying inward currents may also explain progressively increasing APDc and FPDc for nilotinib and dofetilide (Lu et al., 2012; Talajic et al., 1987; Yang et al., 2014) .
Overall, of 20 drugs studied both in acute and chronic experiments (including pentamidine, not shown in Table 1 ) that exhibit clinical QTc prolongation, 17 caused APDc prolongation in at least one iPSC-CM type (16 in Cor.4U and 13 in iCell cardiomyocytes) and 16 caused FPDc prolongation in at least one iPSC-CM type (16 in Cor.4U and 10 in iCell cardiomyocytes). Of 14 drugs associated with TdP risk, arrhythmias were observed for 10 drugs in acute or chronic (amiodarone, pentamidine) experiments in at least one cell type-assay combination. Lack of arrhythmic beating in iPSC-CMs for the four remaining drugs associated with clinical TdP (bepridil, chlorpromazine, terfenadine, and azithromyocin), could be due to differences in relative levels of expression of individual ion channels. For example, higher expression of Cav1.2 in iPSC-CMs (vs adult ventricles) may increase the chance that the arrhythmic potential of hERG block is offset. Indeed, with the exception of azithromycin, each of these drugs shows blockade of Cav1.2 in the tested dose rage. Moreover, it should be noted that with the exception of bepridil, these drugs stopped spontaneous beating of iPSC-CMs at the highest studied doses. The correlation between drug effects in iPSC-CMs with clinical cardiotoxic effects was observed despite the relative immaturity of current iPSC-CMs previously discussed (Hoekstra et al., 2012; Knollmann, 2013) and also confirmed in this study (immature phenotype, spontaneous membrane depolarizations, imperfect gene profiles when compared with adult cardiomyocytes). In addition to the ion channel encoding genes presented in this study, KCNJ2 encoding inward rectifier potassium channel protein Kir2.1 (IK1 current) is known to be particularly underexpressed in iPSC-CMs (Hoekstra et al., 2012) . Luckily, this channel is rarely affected by therapeutic drugs and the drugs in this study had a negligible effect on IK1 current . While human iPSC-CMs offer distinct advantages over isolated animal cardiomyocyte for drug safety assessment by providing an unlimited and homogeneous source of human-derived cells, the development of more mature iPSC-CMs could potentially further improve predictability of the assays based on these cells.
Study Limitations
Execution of dose-response experiments through sequential addition of ascending drug doses to the same well (vs parallel application of different doses to different wells) allows more data points to be obtained from a single well, and allows effects of all doses to be compared with a single baseline control reading. However, the longer time required to complete the full experiment increases the risk of confounding time-dependent drug effects. In addition, each dose was added every hour for the VSD study, and every 30 min for the MEA study, which could explain platform-specific differences for time-dependent drug effects. Based on our results on negative controls and chronic experiments with a limited subset of the drugs, we estimate these effects to be minimal for many drugs, but we cannot completely rule it out for each individual drug. Furthermore, studying only four doses of each drug could not be optimal for detecting drug-induced arrhythmias, it is possible that the observed cessation of spontaneous beating at the highest doses would be preceded by arrhythmic events at a lower dose in an experiment with more drug concentrations assayed. It is likely that when using these methods in real life drug candidate screening a finer grid of doses would be assayed. Full control of the beating rate in spontaneously beating iPSCCMs was not possible under physiological conditions (i.e. pacing at the rates below the intrinsic rate is not effective). To account for the dependence of action potential on the beating rate in iPSC-CMS an empirical formula, Bazet (Hernandez et al., 2016; Kim et al., 2010) or Fridericia (Lewis et al., 2015; Maddah et al., 2015) is usually used, that may not accurately correct for the rate dependence in the wide range of beating rates observed after drug treatments. The need for the forced rate correction would be overcome in a more mature and pure ventricular iPSC-CMs that did not demonstrate spontaneous depolarizations.
The parallel study of the drug effects on two iPSC-CMs lines studied using two different platforms would not be possible without some differences in the experimental design necessary to manage the performance of certain cell type/platform combinations. As a result, there were variations in how the experiments were performed for each of the combinations, including cell plating density, plate coating substrate, time in culture before drug studies began, cell culture media and the timing of the recordings. It is encouraging that despite the variations in the protocols the results of the study were largely consistent between four combinations of cell types and recording platforms.
Each of the iPSC-CM lines used in our study originated from a single healthy donor. A single batch of the cell lines was used for all of the experiments to minimize the variability. While improving the consistency of the results, this approach does not account for the genetic predisposition of individual patients that can play a pivotal role in defining the clinical risk of arrhythmia for individual patients. In addition, drug-induced TdP often occurs in patients with pre-existing cardiac disease. iPSC-CMs used in this study do not reflect patients with preexisting cardiac disease.
Finally, the chosen number of replicates of each drug concentration (3) represented a balance with the desire to test a large number of drugs (26) on two cell types and two different platforms. The goal of this study was to have a broad characterization of iPSC-CM physiology and pharmacology that can guide future work for best practices and verification under the CiPA initiative, where more replicates can be tested if required.
CONCLUSIONS
Concentration-dependent analysis of drug effects on spontaneous electrical activity in iPSC-CMs, using both VSD and MEA platforms, yielded good correlation between drug-induced APDc and FPDc prolongation and clinical QTc prolongation, and between the presence of in vitro and clinical arrhythmias, with some limitations and differences. Spontaneous action or field potentials in iPSC-CMs were sensitive to hERG blocking drugs (causing APDc and FPDc prolongation and arrhythmias) and ICaL-blocking drugs (causing APDc and FPDc shortening and prevention of hERG-related arrhythmias), with a more variable sensitivity to blockers of late-INa. The present results, in combination with those of other recent studies, highlight iPSC-CMs as a promising new in vitro technology that can be included in proarrhythmia assay paradigms, such as that proposed in CiPA. While some discrepancies exist between iPSC-CM assays and clinical experience, under CiPA they would be combined with patch clamp assessment of individual ion channels and in silico modeling. In combination, this is likely to be a substantial improvement in efficiency and predictivity over the present focus on hERG binding and assessment of clinical QTc prolongation late in drug development. An international multi-site validation study with standardized protocols is warranted.
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